Cargando…
Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer
SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma (PDAC), comprising 90–95% of all pancreatic cancers, is one of the deadliest human cancers, with a gloomy prognosis and ~6-month median survival in metastatic tumors. Even patients with resectable tumors show a poor survival rate after surgery. Thus,...
Autores principales: | Mollinedo, Faustino, Gajate, Consuelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394177/ https://www.ncbi.nlm.nih.gov/pubmed/34439330 http://dx.doi.org/10.3390/cancers13164173 |
Ejemplares similares
-
Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine
por: Bonilla, Ximena, et al.
Publicado: (2015) -
Mitochondrial Targeting Involving Cholesterol-Rich Lipid Rafts in the Mechanism of Action of the Antitumor Ether Lipid and Alkylphospholipid Analog Edelfosine
por: Mollinedo, Faustino, et al.
Publicado: (2021) -
Induction of Apoptosis in Human Pancreatic Cancer Stem Cells by the Endoplasmic Reticulum-Targeted Alkylphospholipid Analog Edelfosine and Potentiation by Autophagy Inhibition
por: Gajate, Consuelo, et al.
Publicado: (2021) -
In Vitro and In Vivo Anti-Schistosomal Activity of the Alkylphospholipid Analog Edelfosine
por: Yepes, Edward, et al.
Publicado: (2014) -
Correction: In Vitro and In Vivo Anti-Schistosomal Activity of the Alkylphospholipid Analog Edelfosine
Publicado: (2015)